Regeneron Pharmaceuticals (REGN) Invested Capital (2016 - 2025)
Historic Invested Capital for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $32.0 billion.
- Regeneron Pharmaceuticals' Invested Capital rose 203.87% to $32.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.0 billion, marking a year-over-year increase of 203.87%. This contributed to the annual value of $32.0 billion for FY2025, which is 203.87% up from last year.
- According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Invested Capital is $32.0 billion, which was up 203.87% from $31.0 billion recorded in Q3 2025.
- Regeneron Pharmaceuticals' 5-year Invested Capital high stood at $32.0 billion for Q4 2025, and its period low was $14.0 billion during Q1 2021.
- In the last 5 years, Regeneron Pharmaceuticals' Invested Capital had a median value of $24.8 billion in 2022 and averaged $25.1 billion.
- Per our database at Business Quant, Regeneron Pharmaceuticals' Invested Capital soared by 8999.16% in 2021 and then surged by 203.87% in 2025.
- Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Invested Capital stood at $20.7 billion in 2021, then rose by 18.78% to $24.6 billion in 2022, then increased by 13.43% to $28.0 billion in 2023, then increased by 12.1% to $31.3 billion in 2024, then rose by 2.04% to $32.0 billion in 2025.
- Its Invested Capital was $32.0 billion in Q4 2025, compared to $31.0 billion in Q3 2025 and $29.9 billion in Q2 2025.